Literature DB >> 18581209

Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.

Afraa Zrieki1, Robert Farinotti, Marion Buyse.   

Abstract

PURPOSE: Elevated expression of the ABC transporters P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) seems to correlate with multidrug resistance of cancer cells. In this study we investigated the effect of COX inhibitors in modulating P-gp and BCRP expression and P-gp activity in Caco-2 cells.
METHODS: mRNA and protein expression of MDR1 and BCRP were evaluated by real time PCR and western blot respectively. The activity of P-gp was measured by intracellular accumulation of rhodamine123 or 3H-Digoxin.
RESULTS: The chronic exposure of Caco-2 to indomethacin heptyl ester (indo HE) (0.4 muM) or nimesulide (10 muM) (selective COX-2 inhibitors) and naproxen (6 muM) (non selective inhibitor COX-1/COX-2) significantly decreased the expression and activity of P-gp. In contrast, the acute treatment by nimesulide and naproxen did not modify these parameters while indo HE treatment (48-72 h) caused a protein decrease and a functional inhibition of P-gp. Unexpectedly, the short-term treatment with naproxen induced an important increase of BCRP expression, but this induction was lost after long-term treatment. No modification of BCRP expression was observed after indo HE or nimesulide treatment.
CONCLUSION: Our observations suggest a possible down regulation of P-gp by COX inhibitors, which may enhance the accumulation of chemotherapy agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18581209     DOI: 10.1007/s11095-008-9596-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  42 in total

Review 1.  Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.

Authors:  C Patrono; P Patrignani; L A García Rodríguez
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Prostaglandin endoperoxide H synthases-1 and -2.

Authors:  W L Smith; D L Dewitt
Journal:  Adv Immunol       Date:  1996       Impact factor: 3.543

3.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.

Authors:  Maria Chiara Zatelli; Andrea Luchin; Daniela Piccin; Federico Tagliati; Arianna Bottoni; Cristina Vignali; Marta Bondanelli; Ettore C degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin.

Authors:  A Geick; M Eichelbaum; O Burk
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

7.  Hormonal regulation of oligopeptide transporter pept-1 in a human intestinal cell line.

Authors:  M Thamotharan; S Z Bawani; X Zhou; S A Adibi
Journal:  Am J Physiol       Date:  1999-04

8.  Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.

Authors:  A S Kalgutkar; A B Marnett; B C Crews; R P Remmel; L J Marnett
Journal:  J Med Chem       Date:  2000-07-27       Impact factor: 7.446

9.  Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.

Authors:  Ulrike Puhlmann; Christina Ziemann; Gudrun Ruedell; Hagen Vorwerk; Dirk Schaefer; Claudia Langebrake; Peter Schuermann; Ursula Creutzig; Dirk Reinhardt
Journal:  J Pharmacol Exp Ther       Date:  2004-10-22       Impact factor: 4.030

10.  Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.

Authors:  Omar Alqawi; Susan Bates; Elias Georges
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

View more
  14 in total

1.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

2.  Effect of prostaglandin E2 on multidrug resistance transporters in human placental cells.

Authors:  Clifford W Mason; Gene T Lee; Yafeng Dong; Helen Zhou; Lily He; Carl P Weiner
Journal:  Drug Metab Dispos       Date:  2014-09-26       Impact factor: 3.922

Review 3.  Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs).

Authors:  Megan C Herink; Yan F Zhuo; Craig D Williams; Thomas G DeLoughery
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

4.  Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

5.  Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.

Authors:  Chen Chen; Hui Ling Shen; Jing Yang; Qiao Yun Chen; Wen Lin Xu
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-14       Impact factor: 4.553

6.  Modulation of P-gp expression by lapatinib.

Authors:  Gráinne Dunne; Laura Breen; Denis M Collins; Sandra Roche; Martin Clynes; Robert O'Connor
Journal:  Invest New Drugs       Date:  2010-07-06       Impact factor: 3.850

7.  Potency of non-steroidal anti-inflammatory drugs in chemotherapy.

Authors:  Lucia Hiľovská; Rastislav Jendželovský; Peter Fedoročko
Journal:  Mol Clin Oncol       Date:  2014-10-16

8.  The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.

Authors:  Cyril Sobolewski; Claudia Cerella; Mario Dicato; Lina Ghibelli; Marc Diederich
Journal:  Int J Cell Biol       Date:  2010-03-17

9.  The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.

Authors:  Jennifer N Dulin; Meredith L Moore; Raymond J Grill
Journal:  J Neurotrauma       Date:  2013-01-23       Impact factor: 5.269

10.  The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.

Authors:  Vincenzo Pagliarulo; Patrizia Ancona; Mauro Niso; Nicola Antonio Colabufo; Marialessandra Contino; Luigi Cormio; Amalia Azzariti; Arcangelo Pagliarulo
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.